LivaNova PLC (LIVN) Receives Average Rating of “Hold” from Analysts
Shares of LivaNova PLC (NASDAQ:LIVN) have received an average rating of “Hold” from the eight brokerages that are presently covering the company. Six equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $69.00.
Several analysts have issued reports on LIVN shares. WBB Securities restated a “hold” rating and issued a $60.00 price objective on shares of LivaNova PLC in a research note on Wednesday, August 31st. Piper Jaffray Cos. reiterated an “overweight” rating and set a $59.00 target price (down previously from $61.00) on shares of LivaNova PLC in a research note on Thursday, July 7th.
Shares of LivaNova PLC (NASDAQ:LIVN) traded up 0.57% during mid-day trading on Tuesday, reaching $56.94. The company had a trading volume of 121,966 shares. The stock’s market capitalization is $2.78 billion. LivaNova PLC has a 12-month low of $46.79 and a 12-month high of $70.95. The firm’s 50 day moving average is $59.75 and its 200-day moving average is $54.36.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/livanova-plc-livn-receives-average-rating-of-hold-from-analysts.html
In other LivaNova PLC news, major shareholder Two S.C.A. Equinox sold 391,379 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $60.69, for a total value of $23,752,791.51. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jacques Gutedel sold 4,000 shares of the firm’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $60.52, for a total value of $242,080.00. Following the completion of the sale, the insider now directly owns 10,948 shares in the company, valued at approximately $662,572.96. The disclosure for this sale can be found here. 0.70% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of LIVN. PNC Financial Services Group Inc. increased its stake in shares of LivaNova PLC by 1.9% in the second quarter. PNC Financial Services Group Inc. now owns 2,916 shares of the company’s stock worth $147,000 after buying an additional 54 shares in the last quarter. Creative Planning increased its stake in shares of LivaNova PLC by 4.3% in the third quarter. Creative Planning now owns 2,085 shares of the company’s stock worth $125,000 after buying an additional 85 shares in the last quarter. State Treasurer State of Michigan increased its stake in shares of LivaNova PLC by 0.6% in the second quarter. State Treasurer State of Michigan now owns 17,100 shares of the company’s stock worth $859,000 after buying an additional 100 shares in the last quarter. Retirement Systems of Alabama increased its stake in shares of LivaNova PLC by 0.4% in the second quarter. Retirement Systems of Alabama now owns 55,069 shares of the company’s stock worth $2,766,000 after buying an additional 238 shares in the last quarter. Finally, Advisory Services Network LLC increased its stake in shares of LivaNova PLC by 7.8% in the second quarter. Advisory Services Network LLC now owns 3,508 shares of the company’s stock worth $176,000 after buying an additional 253 shares in the last quarter. 63.66% of the stock is currently owned by hedge funds and other institutional investors.
LivaNova PLC Company Profile
LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.